Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry
暂无分享,去创建一个
C. Campochiaro | L. Dagna | P. Sfikakis | V. Caggiano | R. Giacomelli | E. Bartoloni | A. Vitale | Claudia Fabiani | G. Emmi | G. Lopalco | B. Frediani | F. Iannone | L. Cantarini | F. Cardinale | P. Ruscitti | G. Ragab | A. Balistreri | K. Laskari | G. Conti | M. Maggio | E. Więsik-Szewczyk | C. Gaggiano | F. La Torre | J. Sota | A. Tufan | I. Almaghlouth | R. Pereira | I. Mattioli | Gaafar Ragab | Ewa Więsik-Szewczyk
[1] A. Erden,et al. Derivation and Validation of Adult Still Activity Score (SAS). , 2022, Joint Bone Spine.
[2] K. Minden,et al. Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the German Society of Pediatric and Juvenile Rheumatic Diseases (GKJR): New perspectives on interdisciplinary care. , 2022, Clinical immunology.
[3] P. Sfikakis,et al. Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry. , 2022, Seminars in arthritis and rheumatism.
[4] B. Ogunjimi,et al. Development and Implementation of the AIDA International Registry for Patients With Still's Disease , 2022, Frontiers in Medicine.
[5] B. Bieth,et al. Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses , 2022, Rheumatology and Therapy.
[6] R. Cimaz,et al. CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REAL-LIFE DATA FROM A RETROSPECTIVE ITALIAN COHORT. , 2021, Rheumatology.
[7] P. Hur,et al. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. , 2021, Seminars in arthritis and rheumatism.
[8] D. Foell,et al. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry , 2021, Pediatric Rheumatology.
[9] P. Sfikakis,et al. Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. , 2020, Seminars in arthritis and rheumatism.
[10] A. Vitale,et al. Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease , 2020, Mediators of inflammation.
[11] S. Takei,et al. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients , 2020, Modern rheumatology.
[12] E. Feist,et al. Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial , 2020, Annals of the Rheumatic Diseases.
[13] G. Cavalli,et al. Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes , 2020, Frontiers in Medicine.
[14] K. Michaud,et al. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures , 2019, Arthritis care & research.
[15] G. Cavalli,et al. Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response , 2019, Front. Pharmacol..
[16] A. Pistorio,et al. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis , 2019, The Journal of Rheumatology.
[17] A. Tomelleri,et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease , 2019, Arthritis Research & Therapy.
[18] T. Barnetche,et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy , 2019, Arthritis Research & Therapy.
[19] Yoshiya Tanaka,et al. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial , 2018, Annals of the rheumatic diseases.
[20] N. Wulffraat,et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus , 2018, The Journal of Rheumatology.
[21] D. Foell,et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials , 2018, Annals of the rheumatic diseases.
[22] R. Schneider,et al. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. , 2018, Clinical and experimental rheumatology.
[23] K. Minden,et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry , 2017, Arthritis Research & Therapy.
[24] M. Valenti,et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers , 2016, BMC Medicine.
[25] L. Punzi,et al. A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study , 2016, Front. Pharmacol..
[26] A. Brachat,et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity , 2015, Pediatric Rheumatology.
[27] M. González-Gay,et al. Efficacy of Anakinra in Refractory Adult-Onset Still's Disease , 2015, Medicine.
[28] F. Martinon,et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart , 2014, Immunologic Research.
[29] C. Bombardier,et al. Description of Active Joint Count Trajectories in Juvenile Idiopathic Arthritis , 2014, The Journal of Rheumatology.
[30] J. Haas,et al. Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course , 2014, Pediatric Rheumatology.
[31] N. Wulffraat,et al. Effectiveness of First‐Line Treatment With Recombinant Interleukin‐1 Receptor Antagonist in Steroid‐Naive Patients With New‐Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study , 2014, Arthritis & rheumatology.
[32] T. Beukelman. Faculty Opinions recommendation of Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. , 2014 .
[33] A. Yachie,et al. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. , 2013, Cytokine.
[34] K. Beullens,et al. Results From a Prospective Cohort Study , 2013 .
[35] Andrew I. Shulman,et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. , 2011, Arthritis and rheumatism.
[36] M. Schiller,et al. Clinical Manifestations but not Cytokine Profiles Differentiate Adult-onset Still’s Disease and Sepsis , 2010, The Journal of Rheumatology.
[37] M. Govoni,et al. Adult-onset Still’s disease , 2009, Rheumatology International.
[38] M. Suarez‐Almazor,et al. International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .
[39] J. Piette,et al. Proposal for a New Set of Classification Criteria for Adult-Onset Still Disease , 2002, Medicine.
[40] T. Mimori,et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. , 2001, Rheumatology.
[41] M. Akizuki,et al. Preliminary criteria for classification of adult Still's disease. , 1992, The Journal of rheumatology.
[42] L. Cooperstein,et al. Adult-onset Still's disease. Clinical course and outcome. , 1987, Arthritis and rheumatism.